Written and maintained by CASRAI Editorial Board
Published
On this page
“Research use only” (RUO) is a labeling statement that US regulation allows on an in vitro diagnostic (IVD) product that is still in the laboratory research phase of development and is not represented as an effective diagnostic. Under 21 CFR 809.10(c)(2)(i) the label must read “For Research Use Only. Not for use in diagnostic procedures.” The statement marks an intended use; it does not approve a product, and it does not make a product suitable for clinical testing.
Ask CASRAI · free to tryQuestion about this guide? Ask CASRAI answers with linked sources. 2 free questions a day, no account.
What RUO is and who regulates it
In the United States the Food and Drug Administration (FDA) regulates IVD products as medical devices. A product that has not been approved, cleared or licensed for any use may still be shipped for research if it is labeled and distributed within the limited exemptions in the labeling regulation. The RUO statement is one of those exemptions. The FDA’s final guidance on RUO and investigational-use-only (IUO) products, issued in November 2013 by the Center for Devices and Radiological Health with the Center for Biologics Evaluation and Research, explains how the agency reads them. The guidance is non-binding, but it is the clearest statement of how FDA judges whether an RUO label is genuine.
The guidance describes both RUO and IUO products as IVD products under development that are not approved for clinical diagnostic use, and as exempt from most regulatory controls, including the investigational device exemption (IDE) rules. It covers products that are not cleared, approved or licensed for any use. It does not address off-label use of an approved or cleared product.
Where the requirement comes from: 21 CFR 809.10(c)
Section 809.10 of Title 21 sets the labeling requirements for IVD products. Paragraph (c) exempts the shipment of an IVD from the general labeling requirements of paragraphs (a) and (b) when one of two conditions is met. Either the product is the subject of an investigation under part 812 (the investigational device exemption regulation) and complies with that part, or it is not subject to part 812 and falls under paragraph (c)(2). Paragraph (c)(2) has two parts:
- (c)(2)(i), laboratory research phase. For a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product, all labeling must bear, prominently placed, the statement “For Research Use Only. Not for use in diagnostic procedures.”
- (c)(2)(ii), product testing before full commercial marketing. For a product being shipped for testing before full commercial marketing, for example for comparison with other methods, all labeling must bear the statement “For Investigational Use Only. The performance characteristics of this product have not been established.”
The data table below sets the three routes side by side with the exact label wording and the condition attached to each. The regulation text was checked against the Cornell Legal Information Institute copy of the Code of Federal Regulations on 2026-11-17.
What RUO products may be used for
The guidance names two situations in which an RUO label is accurate.
Products under development
An RUO product, in the guidance’s wording, is an IVD product in the laboratory research phase of development that is being shipped or delivered for an investigation not subject to part 812. The guidance gives examples: tests in development to identify the methodology, components or analytes; instruments and software under development; and reagents under development, where the work concerns production methods, purification, shelf life or storage.
Instruments and reagents for non-clinical laboratory research
The guidance also recognises RUO-labeled instruments and reagents used in non-clinical laboratory research where the product is not itself the object of the research. Its example is research to isolate a gene linked to a disease. The condition is that the instruments and reagents are not intended to produce results for clinical use. For a research laboratory, that is the ordinary case: buying an RUO reagent or instrument for research is consistent with its label, while reporting patient results from it is not.
Software
Software labeled RUO or IUO may be distributed for research or investigational use to entities that conduct research with it.
An RUO label does not settle the question
The guidance is explicit that the mere placement of an RUO or IUO label on an IVD product does not make the device exempt from otherwise applicable clearance, approval or other requirements. What decides the status of the product is its intended use, which under 21 CFR 801.4 is the objective intent of the people legally responsible for its labeling. FDA states that it considers the totality of the circumstances, and that it may treat instructions for use and package inserts as evidence.
A product intended for clinical diagnostic use must meet the requirements of the Federal Food, Drug, and Cosmetic Act that apply to it, which the guidance lists as including establishment registration and device listing, current good manufacturing practice, and adverse event reporting, among others. Premarket pathways for such products are covered in the guide to FDA premarket approval, and clinical laboratory testing is regulated separately under the framework described in CLIA certification.
Practices FDA treats as inconsistent with an RUO label
The guidance lists evidence that conflicts with RUO status. For compliance, quality and purchasing staff, the list works as a screen for how a supplier presents an RUO product. FDA describes the following as inconsistent with an RUO or IUO designation:
- Statements in labeling, advertising or promotion, including performance claims, that suggest clinical diagnostic use.
- Instructions for clinical interpretation of results, or clinical information about them.
- Product names that suggest clinical diagnostic use.
- Statements that clinical laboratories can validate the product and offer it as a laboratory developed test.
- Soliciting business from clinical laboratories, for example routine sales calls to clinical laboratories that do not perform research.
- Specialised technical support, such as help with clinical validation, as distinct from generic maintenance or software updates.
- Relabeling an existing clinical product as RUO without changing how it is distributed, which FDA describes as likely to be inconsistent with RUO status.
Some manufacturers ask customers to certify that they will not use an RUO or IUO product in a way that is inconsistent with its label. The guidance treats such a certification program as one factor only. It states that certification would not relieve manufacturers of their responsibilities.
RUO and IUO compared
The two labels are often confused because both are written for products that are not yet approved for clinical use. The difference is the stage of development: RUO is for the laboratory research phase, and IUO is for product testing before full commercial marketing. The regulation gives each its own required wording, and neither wording may be used for a product that is being used or promoted as a clinical diagnostic. Studies that evaluate IVD performance in a clinical trial setting raise further questions, which are covered in the dictionary entry on IVD in clinical trials.
A checklist for laboratory and procurement staff
The checklist below uses only conditions that appear in 21 CFR 809.10(c) and the FDA guidance. It is not legal advice and it does not replace an institution’s own regulatory review.
- Check that the label carries the full required statement, “For Research Use Only. Not for use in diagnostic procedures.”, placed prominently, and that the same restriction appears on all labeling.
- Confirm that the intended work is laboratory research, or development of the product itself, and not the generation of results for clinical use.
- Read the supplier’s materials for the conflicting practices listed above, such as clinical interpretation instructions, clinical performance claims or product names that suggest diagnostic use.
- Treat a supplier’s certification form as a record of the buyer’s stated use. According to the guidance it does not shift the manufacturer’s responsibility for how the product is labeled and marketed.
- If a result from an RUO product would be used in patient care, treat that as a different intended use that the RUO label does not cover, and route it to the institution’s regulatory or laboratory director function.
Sources
- 21 CFR 809.10, Labeling for in vitro diagnostic products, Cornell Legal Information Institute, checked 2026-11-17.
- 21 CFR 801.4, Meaning of intended uses, Cornell Legal Information Institute, checked 2026-11-17.
- Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only, FDA guidance landing page, checked 2026-11-17.
- Guidance for industry and FDA staff, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only (PDF, November 2013), FDA, checked 2026-11-17.
Data: US labeling routes for unapproved IVD products shipped for research or testing (21 CFR 809.10(c))
Compares the three shipment routes in 21 CFR 809.10(c): investigation under part 812, research use only, and investigational use only, with the exact required label wording and the condition for each. Compiled from the regulation text and FDA's 2013 guidance.
Coverage: United States.
| Route | Regulation paragraph | Development stage or condition | Required label statement |
|---|---|---|---|
| Research use only (RUO) | 21 CFR 809.10(c)(2)(i) | Product in the laboratory research phase of development, not represented as an effective in vitro diagnostic product, and not subject to part 812 | For Research Use Only. Not for use in diagnostic procedures. |
| Investigational use only (IUO) | 21 CFR 809.10(c)(2)(ii) | Product testing before full commercial marketing, not subject to part 812 | For Investigational Use Only. The performance characteristics of this product have not been established. |
| Part 812 investigation | 21 CFR 809.10(c)(1) | Investigation subject to part 812, with the shipment complying with part 812 | Governed by part 812 (investigational device exemption) |
Sources
- 21 CFR 809.10 (accessed 2026-11-17)
- FDA guidance: Distribution of IVD Products Labeled for RUO or IUO (accessed 2026-11-17)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







